热门资讯> 正文

吉利德的Trodelvy获得了新的乳腺癌适应症

2026-06-25 04:37

The US FDA has approved Gilead Sciences' (GILD) Trodelvy (sacituzumab govitecan) as a first-line treatment as monotherapy and in combination with Merck's (MRK) Keytruda (pembrolizumab) for triple-negative breast cancer.
The monotherapy indication was granted based on results from the ASCENT-03 trial, while the combo indication saw support from ASCENT-04/KEYNOTE D-19.
Trodelvy is also approved for HR+/HER- metastatic breast cancer.

More on Gilead Sciences

Gilead Sciences: The Market Is Underestimating Its Growth Runway
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program
Gilead weekly Yeztugo HIV pill sNDA accepted by FDA
Merck, Gilead share positive phase 3 results from combination HIV pill

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。